CERC 501

Drug Profile

CERC 501

Alternative Names: CERC501; LY 2456302

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Janssen Pharmaceuticals; Rockefeller University
  • Class Drug withdrawal therapies
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder; Smoking withdrawal
  • Phase I Alcoholism
  • Clinical Phase Unknown Cocaine abuse

Most Recent Events

  • 17 Aug 2017 Janssen Pharmaceuticals acquires CERC 501 from Cerecor
  • 30 May 2017 Clinical trials in Cocaine abuse in USA (PO) prior to May 2017
  • 01 May 2017 Efficacy data from the phase II RAPID KOR trial in Major depressive disorder released by Cerecor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top